Gaucher Treatment Drug prGCD Newly Approved

Although, prGCD, a new drug used to treat patients with a unique genetic disorder – Gaucher disease, has not received full market approval, the U.S. FDA has said that physicians may utilize the drug for treatment.

The Associated Press has reported that the FDA has endorsed a treatment procedure that will permit Protalix BioTherapeutics Inc. to provide clinical trial patients with prGCD.  This comes as a result of an FDA inspection that has lead to a shortage of Cerezyme, due to the fact they were ordered to abandon most of their ingredients.

According to the AP, under the FDA’s treatment procedure, the clinical trial patients will be treated with prGCD for free until the drug is fully approved.